Development of Fluorinated Sulfamoylbenzamide Derivatives as Antiviral Agents aga

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43AI104066-01
Agency Tracking Number: R43AI104066
Amount: $294,674.00
Phase: Phase I
Program: SBIR
Awards Year: 2013
Solicitation Year: 2013
Solicitation Topic Code: NIAID
Solicitation Number: PA12-090
Small Business Information
3805 OLD EASTON RD, DOYLESTOWN, PA, 18902-8400
DUNS: 828761697
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 (215) 589-6350
Business Contact
Phone: (215) 589-6350
Research Institution
DESCRIPTION (provided by applicant): This is a phase I proposal to determine the feasibility of developing newly discovered fluorinated sulfamoylbenzamide (FSBA) derivatives as therapeutic agents for the treatment of chronic hepatitis B virus (HBV) infection. These molecules have been identified as inhibitors of HBV pregenomic (pg) RNA encapsidation, which is essential for the subsequent viral DNA synthesis. Distinct from the mechanism of the currently FDA-approved antiviral nucleos(t)ide analogues that inhibit HBV DNA polymerase, pgRNA assembly into nucleocapsid represents a novel therapeutic target and the FSBA compounds should thus complement the current antiviral medications. Through an extensive structure-activity-relationship (SAR) study, we have now obtained FSBA compounds with nanomolar antiviral activity. In this Phase I project, we propose to advance lead FSBA compounds with the most favorable ADME, safety and pharmacokinetics (PK) profiles for antiviral efficacy study in the HBV transgenic mouse model in vivo. Having confirmed the in vivo antiviral efficacy in the transgenic mice model, we will further evaluate the safety profile and antiviral efficacy of the lead FSBAs in HBV infected human chimeric uPA-SCID mice model in Phase II study. At the endof Phase II, we will advance one lead candidate for extensive IND enabling studies, and prepare a case for human clinical trial. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: This is a proposal to develop the newly discovered inhibitors of hepatitis B virus (HBV), fluorinated sulfamoylbenzamide derivatives, into a drug for treatment of chronic hepatitis B. The drug candidate functions through interfering with incorporation of pregenomic RNA, the template for viral DNA synthesis, into nucleocapsids, which is a distinct target from the currently FDA-approved anti-HBV medications. Hence, the drug may be of use by itself or in combination with current medications to achieve extended clinical benefits.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government